郭志德 助理教授

通信地址：厦门大学分子影像暨转化医学研究中心409室

电话：0592-2880651

电子邮箱: gzd666888@xmu.edu.cn

个人简介

郭志德博士毕业于中国原子能科学研究院（导师：杜进研究员、张现忠教授）；2017-2020年于bet体育365官网正规从事博士后研究并入选2017年度“博士后创新人才支持计划”（合作导师：张现忠教授）；2020年入职厦门大学分子疫苗学和分子诊断学国家重点实验室并入选“南强青年拔尖人才支持计划”。主要围绕“放射性分子探针与分子影像”开展相关研究。研究方向包括放射性核素诊疗新探针的研发及其生物免疫响应调控研究。迄今已获授权专利20项，以第一作者/通讯作者在Clin Cancer Res、J Nucl Med、J Med Chem、Adv Mater等期刊上发表原创性成果近40篇。担任中国核学会同位素分会理事及《辐射研究与辐射工艺学报》青年编委。主持国家自然科学基金等课题10项。主持多项与企业合作的放射性新药研发及科技成果转化研究。

入选人才计划及在研/结题项目

博士后创新人才支持计划（2017）

厦门大学南强青年拔尖人才支持计划（2020）、福建省高层次引进人才

主持项目包括：国家自然科学基金项目、厦门大学校长基金、与企业合作的新药转化项目。

获奖经历

华夏医学科技奖三等奖、中华医学科技奖三等奖、博新计划优秀创新成果奖、连续获得第十二至十四届全国放射性药物与标记化合物学术会议优秀青年论文奖、2017 International Molecular Imaging Summit (IMIS2017) “Young Investigator Award”

研究兴趣与方向

放射性药物及分子影像探针

1. 疾病免疫成像及放药&免疫联合新范式（PD1/PD-L1、STING、CD73、VISTA等近十种关键免疫靶点探针的研发；聚焦targeting-triggering-therapy放药&免疫3T新范式）

2. 核素诊疗探针药代动力学调控策略研究（探针构效优化策略研究及基于放射生物学响应的内源信号调控研究）

3. 放射性药物临床转化（针对FAP、PSMA等相关靶点的诊疗探针已与多家医院合作开展临床转化研究）

诚挚欢迎化学、生物学、药学、医学、公共卫生、材料学等专业的优秀学子们报考本组，一起探索放射性药物及分子影像新天地！同时，本组招收科研助理及放药专项研发人员，有意者可随时发送简历或电话联系（长期有效）。

近两年代表性成果（^#共同一作，*通讯作者）

[1] Xuejun Wen, Changrong Shi, Xinying Zeng, Liang Zhao, Lanlin Yao, Zhida Liu, Lixia Feng, Deliang Zhang, Jinxiong Huang, Yesen Li, Qin Lin, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. A paradigm of cancer immunotherapy based on 2-[¹⁸F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect. Clinical Cancer Research 2022, 28:2923-2937.

[2] Lingxin Meng^#, Jianyang Fang^#, Liang Zhao^#, Tingting Wang, Pu Yuan, Zuoquan Zhao, Rongqiang Zhuang, Qin Lin, Haojun Chen*, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting fibroblast activation protein. Journal of Medicinal Chemistry 2022,65:8245-8257.

[3] Xuejun Wen^#, Xinying Zeng^#, Jia Liu, Yiren Zhang,Changrong Shi, Xiaoming Wu, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Synergism of ⁶⁴Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect. Bioconjugate Chemistry 2022. doi: 10.1021/acs.bioconjchem.2c00408.

[4] Xuejun Wen^#, Xinying Zeng^#, Changrong Shi, Jia Liu, Yiren Zhang, Mengqi Shi, Jingchao Li, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy. Advanced Therapeutics 2022. doi: 10.1002/adtp.202200193

[5] Liang Zhao^#, Bo Niu^#, Jianyang Fang^#, Yizhen Pang, Siyang Li, Chengrong Xie, Long Sun, Xianzhong Zhang, Zhide Guo*, Qin Lin, Haojun Chen*. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of ⁶⁸Ga-labeled FAPI dimer. Journal of Nuclear Medicine 2022, 63:862-868.

[6] Xuejun Wen^#, Pengfei Xu^#, MengqiShi#, Jia Liu, Xinying Zeng, Yiren Zhang, Changrong Shi, Jingchao Li, Zhide Guo*, Xianzhong Zhang*, Pek-Lan Khong*, Xiaoyuan Chen*. Evans blue-modified radiolabeledfibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 2022, 12: 422-433.

[7] Jie Zang^#, Xuejun Wen^#, Rong Lin^#, Xinying Zeng, Chao Wang, Mengqi Shi, Xueyuan Zeng, Jiaying Zhang, Xiaoming Wu, Xianzhong Zhang, Weibing Miao*, Pengfei Xu*, Zhide Guo*, Jingjing Zhang*, Xiaoyuan Chen*. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [⁶⁸Ga]Ga-FAPI-RGD. Theranostics 2022, 12: 7180-7190.

[8] Xuejun Wen, Changrong Shi, Liu Yang, Xinying Zeng, Xiaoru Lin, Jinxiong Huang, Yesen Li, Rongqiang Zhuang, Haibo Zhu, Zhide Guo*, Xianzhong Zhang*. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:503-516.

[9] Jianyang Fang^#, Lixia Feng^#, Lingxin Meng^#, Xiaobo Wang, Huanhuan Liu, Lumei Huang, Deliang Zhang, Jindian Li, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. A novel ¹⁸F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging 2022. doi: 10.1007/s00259-022-05959-7.

[10] Lumei Huang^#, Jianyang Fang^#, Shouqiang Hong, Huanhuan Liu, Haotian Zhu, Lixia Feng, Rongqiang Zhuang, Xilin Zhao, Zhide Guo*, Xianzhong Zhang*. MicroPET imaging of bacterial infection with nitroreductase-specific responsive ¹⁸F-labelled nitrogen mustard analogues. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:2645-2654.

[11] Huanhuan Liu^#, Xiaoru Lin^#, Duo Xu, Jingchao Li, Jianyang Fang, Jindian Li, Lingxin Meng, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, and Xianzhong Zhang*. Radioiodinated ethinylestradiol derivatives for estrogen receptor targeting breast cancer imaging. ACS Medicinal Chemistry Letters 2022, 13:203-210.

[12] Yiren Zhang, Xuejun Wen, Yanjie Wang, Xia Yang, Yingxi Chen, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, Xianzhong Zhang*. Longitudinal MicroSPECT Imaging of Systemic Sclerosis Model Mice with ^99mTc-HYNFA via FR Targeting. Molecular Pharmaceutics 2022, doi: 10.1021/acs.molpharmaceut.2c00717

[13] Jindian Li^#, Yingxi Chen^#, Chenyu Peng^#, Xingfang Hong^#, Huanhuan Liu, Jianyang Fang, Rongqiang Zhuang, Weimin Pan, Deliang Zhang*, Zhide Guo*, Xianzhong Zhang*. Micro-SPECT Imaging of Acute Ischemic Stroke with Radioiodinated Riboflavin in Rat MCAO Models via Riboflavin Transporter Targeting. ACS Chemical Neuroscience 2022, 13:1966-1973.

[14] Lanlin Yao^#, Xuejun Wen^#, Wei Guo, Jianyang Fang, Xianzhong Zhang, Zhide Guo*, Jinxiong Huang*, Yesen Li¹*. A novel radiolabeled TMTP1 for long-acting hepatocellular carcinoma therapeutics. Molecular Pharmaceutics 2022,19, 9, 3178-3186.

[15] Lixia Feng, Jianyang Fang, Xinying Zeng, Huanhuan Liu, Jingru Zhang, Zhide Guo*, Rongqiang Zhang*, Xianzhong Zhang*. ⁶⁸Ga-labeled maleimide for blood pool and lymph PET imaging throughcovalent bonding to serum albumin in vivo. ACS Omega 2022, 7:28597-28604.

[16] Xuejun Wen, Xueyuan Zeng, Xingxing Cheng, Xinying Zeng, Jia Liu, Yiren Zhang, Yesen Li, Haojun Chen, Jinxiong Huang*, Zhide Guo*, Xiaoyuan Chen*, Xianzhong Zhang*. PD-L1-targeted radionuclide therapy combined with αPD-L1 antibody immunotherapy synergistically improves the antitumor effect. Molecular Pharmaceutics 2022, 19:3612-3622.

[17] Duo Xu^#, Xiaoru Lin^#, Xinying Zeng^#, Xuejun Wen, Jingchao Li, Yesen Li, Jinxiong Huang, Xiaoyuan Chen, Zhide Guo*, Xianzhong Zhang*. Radioiodinated 4-(p-iodophenyl) butanoic acid modified estradiol derivative for ER targeting SPECT imaging. Analytical Chemistry 2021, 93:13998-14006.

[18] Jingchao Li^#, Shuqi Dai^#, Ruixue Qin, Changrong Shi, Jiang Ming, Xinying Zeng, Xuejun Wen, Rongqiang Zhuang, Xiaoyuan Chen*, Zhide Guo*, Xianzhong Zhang*. Ligand Engineering of Titanium-Oxo Nanoclusters for Cerenkov Radiation-Reinforced Photo/Chemodynamic Tumor Therapy. ACS Appl Mater Interfaces 2021, 13: 54727-54738.